Formulation and evaluation of rapidly disintegrating fenoverine tablets: effect of superdisintegrants.
The objective of this study was to formulate directly compressible rapidly disintegrating tablets of fenoverine with sufficient mechanical integrity, content uniformity, and acceptable palatability to assist patients of any age group for easy administration. Effect of varying concentrations of different superdisintegrants such as crospovidone, croscarmellose sodium, and sodium starch glycolate on disintegration time was studied. Tablets were evaluated for weight variation, thickness, hardness, friability, taste, drug content, in vitro and in vivo disintegration time, and in vitro drug release. Other parameters such as wetting time, water absorption ratio ('R'), and drug-excipient compatibility were also evaluated. The disintegration time of the best rapidly disintegrating tablet formulation among those tested was observed to be 15.9 sec in vitro and 37.16 sec in vivo. Good correlation was observed between disintegration time and 'R' for each of the three superdisintegrants at the concentrations studied. Considering the 'R' values and disintegration time, crospovidone was significantly superior (p < 0.05) compared to the other superdisintegrants tested. Release of drug was faster from formulations containing 6% crospovidone (CP 6) compared to the marketed fenoverine (Spasmopriv(R)) capsules. Similarity factor 'f(2)' (51.5) between dissolution profiles of the rapidly disintegrating tablet formulation CP 6 and the marketed formulation indicated that the two dissolution profiles were similar. Differential scanning calorimetric studies did not indicate any excipient incompatibility, either during mixing or after compression. In conclusion, directly compressible rapidly disintegrating tablets of fenoverine with lower friability, acceptable taste, and shorter disintegration times were obtained using crospovidone and other excipients at optimum concentrations.
Battu
Sunil Kumar
SK
Department of Pharmaceutics, School of Pharmacy, The University of Mississippi, MS 38677, USA.
Repka
Michael A
MA
Majumdar
Soumyajit
S
Madhusudan
Rao Y
RY
D002152:Calorimetry, Differential Scanning; D002626:Chemistry, Pharmaceutical; D006801:Humans; D008297:Male; D010640:Phenothiazines / Q000008:administration & dosage / Q000737:chemistry*; D011786:Quality Control; D012995:Solubility; D013607:Tablets; D013649:Taste; D010879:Piperazines
D010640:Phenothiazines; D013607:Tablets; C048314:fenoverine; D010879:Piperazines